Annovis Bio Reports Quarterly Results for Quarter Ended June 30, 2026

What Happened

• On August 14, 2026, Annovis Bio, Inc. (ANVS) filed a Form 8-K (Item 2.02) announcing that it issued a press release reporting earnings for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99 to the filing and is incorporated by reference.

Key Details

• Filing date: August 14, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended June 30, 2026.
• Exhibit furnished: Press release dated August 14, 2026 (Exhibit 99).
• Technical exhibit: Cover page interactive data file submitted in Inline XBRL (Exhibit 104).

Why It Matters

• Earnings and quarterly results are primary sources for assessing Annovis Bio’s recent revenue, expenses, and financial health; investors should read the furnished press release (Exhibit 99) for the actual numerical results and any management commentary.
• This 8-K notifies the market that those results were released; changes in reported earnings, revenue, guidance, or operational updates in the press release can influence investor decisions and share price.
• Because the 8-K itself does not include the financial figures, review the attached press release and any subsequent filings for detailed metrics and explanations.